

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴ : C12N 15/00, 1/00, C12P 21/02 C07K 13/00	A1	(11) International Publication Number: WO 88/ 00241 (43) International Publication Date: 14 January 1988 (14.01.88)
(21) International Application Number: PCT/US87/01459 (22) International Filing Date: 23 June 1987 (23.06.87) (31) Priority Application Number: 879,423 (32) Priority Date: 27 June 1986 (27.06.86) (33) Priority Country: US (71) Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF WASHINGTON [US/US]; 201 Administration Building, The Graduate School AG-10, Seattle, WA 98195 (US). (72) Inventor: POWELL, Jerry, S. ; 3887 44th Avenue Northeast, Seattle, WA 98105 (US). (74) Agent: BRODERICK, Thomas, F.; Christensen, O'Connor, Johnson & Kindness, 2700 Westin Building, 2001 Sixth Avenue, Seattle, WA 98121 (US).		(81) Designated States: BJ (OAPI patent), CF (OAPI patent), CG (OAPI patent), CM (OAPI patent), FI, GA (OAPI patent), KR, LK, MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NO, RO, SD, SE, SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HUMAN ERYTHROPOIETIN GENE: HIGH LEVEL EXPRESSION IN STABLY TRANSFECTED MAMMALIAN CELLS (57) Abstract The Apa I restriction fragment of the human erythropoietin gene, for producing high titers of biologically active hormone from stably transfected cell lines.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

HUMAN ERYTHROPOIETIN GENE:

HIGH LEVEL EXPRESSION IN STABLY TRANSFECTED MAMMALIAN CELLS

This invention was made in part with Government support under Research Grants HL 16919, AM 19410, AM 01418, and CA 31615 awarded by the National Institutes of Health. The Government has certain rights in this invention.

Field of the Invention

This invention relates generally to the field of genetic engineering, particularly to the expression of glycoprotein products of recombinant genes, and more particularly to the expression of high levels of biologically active human erythropoietin from stably transfected cells.

Background of the Invention

The hormone erythropoietin plays a major role in regulating erythropoiesis, the formation of red blood cells, and deficiencies of erythropoietin result in anemia. Detailed studies of the hormone and attempts at replacement therapy have been difficult due to the scarcity of purified material.

Normal production of human red blood cells requires the secretion of erythropoietin by the kidney, apparently as the mature glycoprotein. In the steady state this hormone circulates in the blood at a concentration of 10 to 18 milliunits (128-230 picograms) per milliliter, and with the stimulus of severe tissue hypoxia (oxygen deficiency) the levels may increase as much as 1000-fold. The elevated hormone level triggers proliferation and differentiation of a population of receptive stem cells in the bone marrow, stimulates hemoglobin synthesis in maturing erythroid cells, and accelerates release of red cells from the marrow into circulation, thereby increasing the red cell mass and ameliorating the hypoxic conditions. Patients with deficiencies of erythropoietin, such as those with chronic renal failure, often suffer severe anemia.

Erythropoietin is a glycoprotein of 34-38 kd with approximately 40% of its molecular weight provided by carbohydrate. At least one disulfide bridge is required for activity. Little is known about the structure of this

hormone, and the details of its synthesis are not well understood. Recent isolations of cDNA and genomic clones provide opportunities to analyze control of erythropoietin production, but the expression of biologically active human erythropoietin in sufficient quantities for replacement therapy has not been achieved.

Summary of the Invention

Pursuant to this disclosure, biologically active human erythropoietin can be expressed at high levels (at nominal titers exceeding two million Units per liter of supernatant) from stably transfected mammalian cell lines. Thus, an abundant source of purified human erythropoietin for clinical applications is provided. Surprisingly high expression of erythropoietin is achieved by transfecting host cell lines with the Apa I restriction fragment of the human erythropoietin gene. The sense strand of the Apa I restriction fragment has a nucleotide sequence corresponding to that shown in FIGURE 1.

Brief Description of the Drawings

FIGURE 1 is a schematic representation of the subject 2426 bp Apa I restriction fragment that contains the human erythropoietin gene sequences;

FIGURE 2 depicts a representative plasmid expression vector (pD11-Ep) that contains the 2426 bp Apa I restriction fragment; and,

FIGURE 3 depicts another expression vector (pBD-EP) carrying the subject Apa I restriction fragment.

Detailed Description of the Preferred Embodiment

In the preferred embodiment, a genetically engineered construction of the Apa I restriction fragment shown in FIGURE 1 is inserted into a mammalian expression vector, such as those shown in FIGURES 2 and 3, and introduced into mammalian cell lines to develop stably transfected cells that produce large amounts of biologically active human erythropoietin. The Apa I restriction fragment of the human erythropoietin gene was selected to maximize efficient transcription of erythropoietin messenger RNA and effective translation and post-translational modification of the RNA into mature biologically active erythropoietin glycoprotein. Specifically, at the 5' end of the erythropoietin gene it was important to remove interfering sequences but retain enhancing sequences. Introns were retained in the Apa I restriction fragment in order to include potentially significant enhancing sequences. At the 3' end of the gene some 3' untranslated sequences were retained to optimize putative regulating sequences. The enhanced expression provided by the Apa I fragment is demonstrated by the consistently high levels of erythropoietin expression

described in the following working examples, using this fragment in concert with two promoters and two cell lines.


The following Examples are presented to illustrate the advantages of the present invention and to assist one of ordinary skill in making and using the same. These Examples are not intended in any way to otherwise limit the scope of the disclosure or the protection granted by Letters Patent hereon.

EXAMPLE 1

Isolation of genomic clones.

A human genomic library in bacteriophage lambda (Cell 15:1157-1174, 1978) was screened using low stringency hybridization conditions and mixtures of oligonucleotide probes as described in Cell 38:287-297, 1984, hereby incorporated by reference.

Oligonucleotide mixtures were prepared using an Applied Biosystems synthesizer and end-labeled using ^{32}P -ATP and T4 polynucleotide kinase. The synthetic oligonucleotides were designed to correspond to portions of the amino terminal amino acid sequence of:



obtained by Yanagawa et al. (J.Biol.Chem. 259:2707-2710, 1984) for the human protein purified from urine of patients with aplastic anemia. To reduce the degeneracy of the codons for the amino acid sequence of this region, the codon usage rules of Grantham et al. (Nucleic Acids Research 8:43-59, 1981) and Jaye et al. (Nucleic Acids Research 11:2325-2335, 1983) were employed. These rules take into account the relatively rare occurrence of CpG dinucleotides in DNA of vertebrates and avoid, where appropriate, potential A:G mismatch pairings. At amino acid position 24, an asparagine was placed as most likely (J.Biol.Chem. 259:2707-2710, 1984). For the amino acids Glu-Ala-Lys-Glu-Ala-Glu-Asn, 2 pools of 72 sequences each were synthesized to correspond to the predicted codons. Thus, one pool was TT(c/t)TC(a/g/t)GC(c/t)TC(c/t)TT(a/g/t)-GCTTC for the 20 nucleotide probe, and the second pool replaced a T with a C at position 18. For the amino acids Glu-Asn-Ile-Thr-Asp-Gly, one pool of sequences (AGC TCC TCC ATC AGT ATT ATT T[c/t]) was constructed for the 23 nucleotide probe.

Plaques which hybridized to the oligonucleotide probes were rescreened at lower density until pure. After initially positive phage clones were plaque-purified, additional sequence information for the erythropoietin gene was published by Jacobs et al. (Nature 313:806-310, 1985). Oligonucleotides were constructed from this information and used to confirm the identity of the positive clones. After Eco RI restriction enzyme digestion of the positive clones, insert DNA was gel-purified and ligated by standard techniques into pUC 13 plasmid previously restriction-digested with Eco RI. DNA sequence was determined by dideoxynucleotide chain termination (Proc.Natl.Acad.Sci.USA 74:5463-5467, 1977) using dATP (α -³⁵S) and the 17-mer universal primer or, in selected regions, specific oligonucleotide primers. ³²P-ATP was from ICN; enzymes were from New England Biolabs or Bethesda Research Laboratories.

Approximately 4.8×10^6 bacteriophage were screened by hybridization of replicate nitrocellulose filters. Three different clones remained positive through plaque purification, and the DNA insert was characterized by restriction mapping and partial dideoxynucleotide sequencing. Two of the three clones contained apparently complete information for the erythropoietin gene. The restriction map and sequence for the 2426 bp Apa I fragment of these clones is shown in FIGURE 1 and was essentially the same as that recently published by Jacobs et al. (Nature 313:806-810, 1985) for the gene for human erythropoietin. The low frequency of phage isolates containing the erythropoietin gene in this amplified library, one in approximately 2×10^6 bacteriophage, is consistent with the suggestion that erythropoietin exists as a single copy in the human genome. Southern blot hybridization of total human genomic DNA with the Apa I fragment or other restriction fragments of the erythropoietin gene indicated only a single hybridizing band with no additional regions of highly homologous DNA.

EXAMPLE 2

Selection of the Apa I restriction fragment.

For construction of expression vectors the Apa I restriction fragment of the erythropoietin gene was obtained using techniques described in Proc. Natl.Acad.Sci.USA 74:5463-5467, 1967, hereby incorporated by reference. Briefly, isolated phage DNA was digested with the restriction enzyme Apa I (Bethesda Research Laboratories) followed by separation on a 1% agarose gel and isolation by electroelution, phenol extraction and ethanol precipitation. The fragment was confirmed by partial sequencing as in Example 1.

Referring to FIGURE 1, the inserted Apa I restriction fragment contained 58 bp of 5' untranslated sequences (nucleotides 0001-0058) followed by

sequences coding for a putative 27 amino acid signal peptide, the mature protein, four putative intervening sequences, and 222 bp of 3' noncoding DNA sequence. At the 5' end of the gene the Apa I site is located 58 base pairs upstream from the ATG start codon (0058) for the protein sequence. This 5' site (0001) was selected to avoid a false start site just upstream from the Apa I restriction site while including putative regulatory sequences considered to be important for efficient ribosomal binding and processing. The Apa I site at the 3' end (2426) was selected to include putative processing signals in most of the 3' untranslated sequences while removing further downstream sequences. The complete erythropoietin gene, including intron sequences, was used in order to include potential regulatory or enhancing sequences located in introns that might contribute to erythropoietin gene expression or protein modification and secretion.

EXAMPLE 3

Construction of expression plasmids carrying the Apa I restriction fragment.

The 2426 bp Apa I restriction fragment containing the intact human erythropoietin gene was inserted into two expression vectors, the pD-11 and pBD constructs, each of which is based on a different mammalian promoter.

The plasmid expression vector pD11 was derived from a previously described plasmid (Nucleic Acids Research 13:841-857, 1985, expressly incorporated herein by reference) and contained the simian virus 40 (SV-40) enhancer sequences and origin of replication as well as the adenovirus-2 major late promoter and tripartite leader sequences. The Apa I fragment of human erythropoietin genomic sequences (FIGURE 1) was gel-purified, and single stranded ends were filled in by treatment with T4 DNA polymerase. Bam HI linkers were ligated to both blunt ends, and the construct was inserted into a unique B-Bam HI restriction site of pD11 in order to direct transcription of the erythropoietin gene from a strong promoter.

The structure of the resulting expression plasmid pD11-Ep carrying the Apa I fragment (Ep) is depicted in FIGURE 2. The plasmid pD11 contains 350 bp of the adenovirus left-terminus (0-1), the origin and enhancer sequences from SV-40 (E), the adenovirus major late promoter (MLP), the adenovirus-2 tripartite leader (L1-3) and third leader 5' splice site (5' ss), an immunoglobulin 3' splice site (3' ss), and the late SV-40 polyadenylation signal (pA) in the Eco RI (RI) restriction site of pML. Recombinant plasmids were cloned in E. coli HB101 and purified by isopycnic centrifugation in cesium chloride. The expression plasmid pD11-Ep is approximately 6500 bp in length. The construction was confirmed by restriction mapping and partial dideoxynucleotide sequencing.

pBD contains the MT-I promoter sequence (Glanville, Durham & Palmiter, Nature 292:267-269, 1981, expressly incorporated herein by reference) and a DHFR selectable marker sequence carried in pUC plasmid. Referring to FIGURE 3, the 2426 bp Apa I restriction fragment (EP) was inserted into a unique Sma I restriction site in pBD to make expression plasmid pBD-EP. The DHFR sequence in pBD-EP was associated with origin and enhancer sequences from SV40 and with Hepatitis B Surface Antigen polyadenylation sequences. pBD-EP was processed essentially as described above for pD11-EP.

While plasmid vectors were used in these confirming experiments, it is contemplated that viral or retroviral expression vectors can likewise be used to introduce the Apa I erythropoietin gene fragment into host cell lines. Suitable DNA viruses for this purpose would include adenovirus or BPV (Bovine Papilloma Virus). Suitable retroviral vectors are also known and available. It is understood that such a retroviral (RNA) vector would carry the anti-sense strand of the Apa I restriction fragment, that is, one having a sequence corresponding to the RNA transcribed from the sense strand shown in FIGURE 1 or to an allele thereof. The retroviral vector would also include sequences for trans-acting factors required for reverse transcription of the viral genome and integration of the DNA form of the virus into the host genome.

EXAMPLE 4

Transfection of mammalian cells.

Each of two mammalian cell lines were transfected with each of the pD11-EP and pBD-EP constructs. Mammalian cell lines, COS-7 (monkey kidney) and BHK (baby hamster kidney), were maintained in Dulbecco's modified essential medium containing 10% fetal calf serum. Cells were passaged and when 50-70% confluent were transfected by the calcium phosphate method (Virology 52:456-467, 1973). BHK derives from kidney epithelial cells, generally regarded as the most likely cell that produces erythropoietin in the natural state when a mammal is anemic or hypoxic. Thus, these cells might recognize critical regulatory sequences in the Apa I fragment of the erythropoietin gene, and then effectively process and produce the erythropoietin glycoprotein.

For transient expression of cells in a 100 mm culture dish a total of 20 µg DNA was used: 10 µg of pD11-EP plasmid containing the erythropoietin gene and 10 µg of carrier salmon sperm DNA. After 48 hours the supernatant was collected, centrifuged at 400 g for 10 minutes to remove cells and debris, and frozen at -20°C. The cells were harvested separately. The results of transfections with pD11-EP alone for transient expression are shown in Table 1. Data are from 3 experiments for each cell type.

TABLE 1

Erythropoietin per ml of culture

<u>Mammalian cells</u>	<u>Micrograms protein</u>	<u>Units (in vitro bioassay)</u>
BHK	3.4 \pm 0.2	270 \pm 16
COS-7	3.2 \pm 0.4	255 \pm 32

The observed levels of erythropoietin secreted into the supernatant of either the COS-7 or BHK mammalian cell lines were approximately 80 times higher than those previously reported for transient expression of a cDNA coding for erythropoietin or for transient expression of other constructs using intact erythropoietin genes.

To establish stable cell lines producing high levels of erythropoietin, either COS-7 or BHK cells were cotransfected with the pD11-Ep plasmid and pDHFR-1a, a plasmid containing a cDNA for dihydrofolate reductase in a similar mammalian expression vector. The transfection procedure was modified so that 5 μ g of pD11-Ep plasmid, 5 μ g of pDHFR-1a plasmid, and 10 μ g of carrier DNA were cotransfected. After additional incubation for 18-24 hours, varying concentrations of methotrexate (10 nM to 1 mM) were added to the cultures. Cells that incorporated the DHFR gene would be viable in the selective medium. After incubation for several more days, viable colonies resistant to methotrexate were isolated, passaged and screened for the presence of erythropoietin bioactivity in the supernatant. Approximately half of the methotrexate-resistant colonies that were assayed secreted detectable erythropoietin activity.

To establish stable cell lines with the expression vector pBD-EP, BHK cells were transfected by the calcium phosphate method. After 18-24 hours, these cultures were subjected to concentrations of methotrexate varying from 1 μ M up to 1 mM. After incubation for several more days, viable colonies resistant to these relatively high levels of methotrexate were isolated, passaged and screened. In this series, all of the methotrexate-resistant colonies that were assayed secreted detectable erythropoietin activity.

In order to optimize the expression of the transcriptional unit containing the erythropoietin gene and the DHFR gene, BHK cell lines containing either pBD-Ep or pD11-Ep and secreting high levels of erythropoietin were passaged several times into increasing concentrations of methotrexate (Nature 316:271-273, 1985). However, rather than a gradual increase in the selective pressure on the cell lines by small incremental steps in the concentration of methotrexate, the cells were immediately challenged with very high levels of

methotrexate (i.e., 1 mM). Only a few cells survived, but those cells would have incorporated the plasmid construction into a region of DNA particularly advantageous for expression (a so-called "hot spot") and/or would have many copies of the constructed transcriptional unit. Thus, the highest producing cell lines were selected in one step. Cell lines (including F 7.2 and S 5.2 listed in Table 2) were considered stable if erythropoietin production remained high for more than 15 passages in the absence of methotrexate selective pressure.

Amounts of erythropoietin activity in the cell pellets could not be determined due to the presence of significant inhibitors of the assay in the cell extracts. Consequently, the results shown in Table 2 do not analyze the intracellular levels of erythropoietin protein but rather the amount of erythropoietin protein produced and secreted into the supernatant by the cell lines.

TABLE 2

Expression of Recombinant Erythropoietin From
Stably Transfected BHK Cell Lines

		Erythropoietin per ml of supernatant	
	Cell Line	Micrograms protein	Units (in vitro bioassay)
	<u>pBD-EP</u>		
	F 1.1	12.4	970
20	F 3.4	32.0	2500
	F 6.1	79.6	6210
	F 7.2	84.1	6728
	<u>pD11-EP</u>		
	S 1.2	6.4	500
25	S 2.4	64.2	5000
	S 5.2	82.1	6400

The observed amounts of erythropoietin secretion correspond to nominal rates of up to almost seven million Units per liter. Such nominal rates are determined by multiplying the observed yield per ml by one thousand to give an anticipated scaled-up production yield per liter.

The observed amounts of erythropoietin secretion using the Apa I fragment were on the order of 300 times greater than those previously reported (Lin et al., Proc.Natl.Acad.Sci.USA 82:7580-7584, Nov. 1985) for a stably transformed CHO cell line containing a different genomic fragment of the human erythropoietin gene.

Control experiments for these transfection assays included supernatants from nontransfected cells and parallel cultures of cells transfected with plasmids containing DNA encoding other proteins, including bacterial chloramphenicol acetyl transferase and human coagulation protein, factor IX. None of the control cultures, mock transfections, or cultured cells transfected with other genes had detectable erythropoietin activity. It was also noted in the above series of experiments with the erythropoietin gene that the levels of expression obtained for selected cell lines were not related to whether the selectable marker was cotransfected along with the erythropoietin gene or was inserted into the Apa I fragment-containing plasmid prior to transfection (data not shown).

Other representative transfection methods suitable for practicing this invention include DEAE-dextran mediated transfection techniques, lysozyme fusion or erythrocyte fusion, scraping, direct uptake, osmotic or sucrose shock, direct microinjection, indirect microinjection such as via erythrocyte-mediated techniques, and/or by subjecting the host cells to electric currents. By transfection is meant the transfer of genetic information, and specifically the information encoded by the Apa I restriction fragment of a human erythropoietin gene, to a cell using isolated DNA, RNA, or synthetic nucleotide polymer. The above list of transfection techniques is not considered to be exhaustive, as other procedures for introducing genetic information into cells will no doubt be developed. The Apa I restriction fragment will typically be operably linked (ligated) to other nucleic acid sequences such as promoter, enhancer, and polyadenylation sequences, prior to transfection. While host cell lines of mammalian origin are described, and kidney epithelial cells are considered to be particularly preferred, it is contemplated that other eukaryotic as well as prokaryotic (bacteria or yeast) host cell lines can be employed in the practice of this invention; very recent introductions of mammalian genes into plant cells offer the potential for employing plant or algal cells as well.

EXAMPLE 5

Erythropoietin expression from transfected cell lines.

The recombinant erythropoietin protein secreted into the supernatant of the transfected cell lines was biologically active, and large amounts of the hormone were secreted: up to 7000 units per milliliter.

The in vitro assay for erythropoietin biological activity was based on the formation of erythroid colonies (from CFU-E; erythroid colony-forming cells) in cultures of mouse bone marrow cells in plasma clot (Blood Cells 4:89-103, 1978). The sensitivity of this assay is about 5 milliunits/ml. The

erythropoietin used as the standard for assay was a partially purified preparation from plasma from anemic sheep (Connaught, Step 3 Ep, Lot 3026). Supernatants were assayed from passaged cell lines grown for 24 hours in fresh medium without methotrexate. The supernatant was diluted 1:200 with medium, and amounts between 1 and 10 microliters were added per milliliter of assay culture containing 2×10^5 marrow cells, 10% bovine citrated plasma, 20% fetal calf serum, 1% bovine serum albumin, and 1.6% beef embryo extract (Gibco). After incubation for 36 to 48 hours the plasma clots were fixed on microscope slides, stained with benzidine for hemoglobin, and erythroid colonies were enumerated. In the absence of added erythropoietin, no CFU-E-derived colonies were detected. Optimal erythroid colony growth (100-150 CFU-E detected per 2×10^4 marrow cells) was observed routinely with 50 mU (0.64 nanograms) erythropoietin per ml of culture. Large amounts of erythropoietin hormones were secreted into the supernatant of the transfected cell lines, see Tables 1 and 2, up to 7000 units per milliliter. Assuming the recombinant erythropoietin has a specific activity equivalent to that of natural erythropoietin (78,000 units per mg protein), the biological assay corresponds to approximately 80 μ g of erythropoietin protein per milliliter.

In addition, supernatants from selected cell lines were assayed for immunologically reactive erythropoietin by competitive radioimmunoassay using a polyvalent anti-human-erythropoietin rabbit anti-serum (J.Cell.Physiol. 118:87-96, 1984). The amount of protein measured by the radioimmunoassay was equivalent to the protein level estimated by the biological assay. These data indicate that the transfected cell lines expressed and secreted erythropoietin protein that was greater than 98% active.

The recombinant erythropoietin produced by the transfected cells was further characterized to demonstrate that these cells were secreting authentic hormone. Selected cell lines were assayed for in vivo erythropoietin activity in exhypoxic polycythemic mice (Nature 191:1069-1087, 1961). Supernatants secreted from the cell lines had potent in vivo biological activity when assayed in the exhypoxic polycythemic mouse. In experiments using partially purified native erythropoietin, it had been noted previously that neuraminidase treatment completely abrogated erythropoietin activity when assayed in the intact animal (J.Biol.Chem. 247:5159-5160, 1958). The loss of activity presumably was due to increased clearance by the liver of the desialated hormone since neuraminidase-treated erythropoietin remained fully active in vitro. The observation of potent in vivo biological activity indicates that the transfected

mammalian cell lines appropriately add carbohydrate and the terminal sialic acids to the erythropoietin protein during post-translational modification.

In separate experiments, the activity of erythropoietin in the in vitro biological assay was neutralized by a neutralizing anti-human erythropoietin antibody added to the culture.

The erythropoietin secreted into the supernatant of representative transfected cell lines was also assayed for proliferative effects on other marrow progenitor cells. Recombinant erythropoietin was assayed for its effect on a variety of progenitors from mouse and human marrow including erythroid colony-forming cells (CFU-E), erythroid burst-forming cells (BFU-E), granulocyte-macrophage precursors (CFU-GM), and mixed-cell colony-forming cells (CFU-Mix) (J.Cell.Physiol.Suppl. 1:79-85, 1982; J.Cell.Physiol. 118:87-96, 1984). Erythroid stem cells exhibited a proliferation response to the recombinant erythropoietin that was parallel to the dose-response relationship found with natural erythropoietin. Neither CFU-GM nor CFU-Mix exhibited any proliferative response to the recombinant erythropoietin at concentrations up to 10 units per milliliter of assay cell culture.

When analyzed by SDS-PAGE under reducing or nonreducing conditions the purified recombinant erythropoietin electrophoresed identically to erythropoietin purified from urine of patients with aplastic anemia. Similar microheterogeneity of the proteins was observed, and the predominant species had identical molecular weights of 34 kD.

While the present invention has been described in conjunction with preferred embodiments, one of ordinary skill after reading the foregoing specification will be able to effect various changes, substitutions of equivalents, and other alterations to the compositions and methods set forth herein. It is therefore intended that the protection granted by Letters Patent hereon be limited only by the definition contained in the appended claims and equivalents thereof.

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. Substantially pure DNA or RNA consisting essentially of nucleotide sequence corresponding to the Apa I restriction fragment of a human erythropoietin gene.

2. The DNA or RNA of Claim 1 wherein the Apa I restriction fragment consists essentially of the nucleotide sequence of either the sense strand shown in FIGURE 1 or the complementary RNA sequence thereof.

3. The DNA or RNA sequence of Claim 1 operably linked to a second nucleic acid sequence capable of effecting expression thereof.

4. The DNA or RNA of Claim 3 wherein the second nucleic acid sequence is selected from one or more of the following: promoter sequences, enhancer sequences, polyadenylation sequences, selectable marker sequences, plasmids, viral and retroviral expression vectors, and retroviral trans-acting factors.

5. Cells containing the DNA or RNA of Claim 3.

6. Cells stably transfected with the DNA or RNA of Claim 3.

7. Cells of Claim 6 selected from the group consisting of eukaryotic cells, yeast, and bacteria.

8. Cells of Claim 7 wherein the eukaryotic cells are of kidney origin.

9. Cells of Claim 8 wherein the kidney cells are epithelial cells.

10. A method of expressing recombinant biologically active human erythropoietin comprising the steps of transfecting a host cell line with DNA, RNA, or nucleotide sequence consisting essentially of the Apa I restriction fragment of a human erythropoietin gene, contacting the transfected cells with culture medium to permit the cells to express erythropoietin, and recovering the expressed erythropoietin.

11. The method of Claim 10 wherein the Apa I restriction fragment is carried on a plasmid or virus.

12. The method of Claim 10 wherein the host cell line is selected from the group consisting of eukaryotic cells, yeast, and bacteria.

13. In a method of expressing recombinant biologically active human erythropoietin from a cell line in contact with an incubating medium, the improvement which comprises incorporating in said method a cell line capable of permitting a yield of erythropoietin in the incubating medium, said cell line having been produced by transfecting a host cell line with DNA, RNA, or nucleotide sequence consisting essentially of the Apa I restriction fragment of a human erythropoietin gene.

14. The method of expressing recombinant biologically active human erythropoietin from a cell line in contact with an incubating medium in accordance with Claim 13, wherein said cell line is capable of permitting a nominal yield of at least two million Units of erythropoietin per liter of incubating medium.

15. The method of Claim 13 wherein said Apa I restriction fragment is carried on a plasmid.

16. The method of Claim 13 wherein said Apa I restriction fragment is carried on a virus.

17. The method of Claim 13 wherein the host cell line is selected from the group consisting of eukaryotic cells, yeast, and bacteria.

18. Human erythropoietin expressed by the cells of Claim 5, 6, 7, 8, or 9.
19. Human erythropoietin expressed by the host cell line of Claim 10, 11, 12, 13, 14, 15, 16, or 17.
20. Biologically active human erythropoietin produced by recombinant DNA means.

DNA:epo:apa.gene
DNA LENGTH: 2426

FIRST NUCLEOTIDE: +1

First nt. 10 20 30 40 50 60 70 80 90 100
+1 CCGCGTGTGG TCACCCGGGG CCCCCCAGGT CCGTGGGGA CCGCGGCCAG GCGGCGAGAT GGGGGTGGAC GGTGATACT CCGGGGCTGG GCGCTCCGCG
+101 CCGCCCCGGGT CCTGTGTTGA GCGGGGATTT AGCGGCCCGGG CTATTGGCCA GGAAGTGGCT GGGTTCAAGG ACCGGGCGACT TGTGAAGGAC CCGGGAAGGG
+201 GGAAGGGGGGT GGGGGCAGCCT CCACGTGCCA GCGGGGACTT GGGGGAGTCC TTGGGGATGG CAAAAACTTG ACCTGTGAAG GGGACACAGT TTGGGGGTTG
+301 AAGGGGAGAA GGTTTGGGGG GTTCTGCTGT GCAAGTGGAG AGGAAGCTGA TAAAGCTGATA ACCTGGGCGC TGGAGCCACC ACTTAICTGC CAGAGGGGGA
+401 GCTCTGTCA CACCAGGATT GAAGTTTGGC CGGAGAGTGG GATGCTGGTA GCTTGGGGGT GGGGTGTGCA CACGGCAGCA GGAATGGAATG AAGGCGAGGG
+501 AAGGAGCACC TGAGTGTCTG CATGTTTGGG GACAGGAGGG ACAGCTTGGG GACAGAGACT GGGGATGAAAG GAAAGTGTTC TTGCACAGCC ACCCTTCTCC
+601 CTCCCGCGCT GACTCTCAGC CTGGCTATCT GTTCTAGAAAT GTCTGCTTG GCTGTGGCTT CTCTGTGCTC TGGTGTGGCT CCTCTGGGC CTCCGAGTCC
+701 TGGGCGCCCC ACCAGGCTC ATCTGTGACA GCGGAGTCTT GCAGAGGTAC CTCTTGGAGG CCAAGAAAGC CGAAGATATC ACAGTGAAGC CCGTTCCGCA
+801 GCAATTCCA CAGAACTAC GCTCAGGGCT TCAGGCACT CTTCCAGAT CAGGAACT CAGGAACT GGGGATGGA GTTGGGAGGC TAGACACTGC
+901 CCCCCATCAT AAGAAATAGT CTGGTGGGCC CAACCATAC CTGGAACTA GGAAGAGAGC AAAGCCAGCA GATCTAGGC CTGTGGGCAAG GGCACAGAGCC
+1001 TTACGGGACC CTTGACTCCC CAGGCTGTGT GCATTTGAGA CAGGCTGTGC TGACACTGC AGATTGAATG AGAATATCAC TGTCCGAGAC ACCAAGTTTA
+1101 ATTCTATGC CTGGAGAGAG ATGGAGGTGA GTTCTTTTT TTTTTTTT CTTTCTTTT GGAGATCTC ATTGGGAGC CTGATTTTGG ATGAAAGGGA

1/3

Fig. 1A.

SUBSTITUTE SHEET

2/3

+1201 GAATGATCGA GGGAAAGGTA AAATGGAGCA GCAGAGATGA GGTGCTCTGG GGCACAGAGC TCAGTCTCTAT AATCCDAGGC TGAGATGGCC GAGATGGGAG
 +1301 AATTGCTTGA GCCCCGGAGT TTCAGACCAA CTTAGGCAGC ATAGTGAAT CCCCATCTC TADAAACATT TAAAAAATT AATCAGGCTGA AGTGGTGCAT
 +1401 GGTGGTAGTC CCAGATATTT GGAAGGCTGA GGCAGAGGGA TGGTGGAGC CCAGGAATTT GAGGCTGCAG TGAGCTGTGA TCACCACT GAACTCCAGC
 +1501 CTCAGTGACA GAGTGAGGCC CTGTCTDAAA AAAGAAAGGA AAAAAAGAAA ATATGAGGG CTGTATGGAA TACGTTCAIT ATTATTCAC TCACTCACTC
 +1601 ACTCATTCAT TCATTCATTC ATTCACAGAG TCTTATGCA TACCTTCTGT TTGCTCAGCT TGCTGCTTGG GGTGCTGTGA GGCACAGGAG GAGAGGCTGA
 +1701 CATCCCTCAG CTGACTCCCA GATCCCACTC CCTGTAGGTC GGCACAGAGC CCGTAGAGGT CTGGCAGGGC CTGGCCCTGC TGTCCGAGGC TGTCTTGCAG
 +1801 GGCACAGGCC TGTGTGTGAA CTCTTCCDAG CCGTGGAGC CCTGCAGCT GCAITGGAT AAAGCCCTCA GTGGCTTGG CAGCTCACC ACTCTGCTTC
 +1901 GGGCTCTGGG AGCCDAGGTTG AGTAGGAGG GACACTTCTG CTTCCTTTT CTGTAGAGAG GGGAGAGGG TCTTGTGAAG GAGTACAGGA ACTGTCTGTA
 +2001 TTCTTCCCT TTCTGTGGCA CTGCAGGAGC CTCTGTGTTT CTCTTGGGA GAGGAGAGCC ATCTCCCTC CAGATGCGGC CTGAGTGTCT CCCTCDBAA
 +2101 CAATCACTGC TGACACTTTC CGCAACTCT TCGAGTCTA CTCGATTC CTCGAGGGA AGCTGAAGCT GTACACAGGG GAGGCTTGA GAGACAGGGGA
 +2201 CAGATGACCA GGTGTGTCCA CCTGGGATA TCCACACT CCTCACCAG CATTTCTGT GCCACACTT CCCCAGGAG TCTTGAGCC GGTCCAGGGG
 +2301 CTTCAGCTC AGCCGAGGCC TGTCCCATGG ACATCTCAGT GGCACCAATG ACATCTCAG GGCACAGGA ACTGTCCAG GAGCAACTCT GAGATCTTAA
 +2401 GATGTACAG GGCACACTTG AGGGCC

Fig. 1B.

SUBSTITUTE SHEET

3/3




Fig. 2.





Fig. 3.

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 87/01459

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC ⁴ : C 12 N 15/00; C 12 N 1/00; C 12 P 21/02; C 07 K 13/00		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC ⁴	C 12 N; C 12 P; A 01 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
III. DOCUMENTS CONSIDERED TO BE RELEVANT*		
Category *	Citation of Document, ¹¹ with Indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP, A, 0148605 (KIRIN AMGEN INC) 17 July 1985 see the whole document --	1-20
X	WO, A, 8503079 (NEW YORK UNIVERSITY) 18 July 1985 see the whole document --	18-20
X	WO, A, 8603520 (GENETICS INSTITUTE) 19 June 1986 see the whole document --	18-20 1-17
A	--	
P,X	Proceedings of the National Academy of Sciences of the USA, vol. 83, no. 17, September 1986 (Washington, DC, USA) J.S. Powell et al.: "Human erythropoietin gene: high level expression in stably transfected mammalian cells and chromosome localization", pages 6465-6469, see the whole document --	1-20
P,X	WO, A, 8604920 (BIOTECHNOLOGY RESEARCH	./.
<p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
15th October 1987	30 NOV 1987	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	M. VAN MOL 	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
E	PARTNERS LTD) 28 August 1986 see the whole document --	18-20
	EP, A, 0236059 (SNOW BRAND MILK PRODUCTS) 9 September 1987 see the whole document -----	18-20

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON

INTERNATIONAL APPLICATION NO. PCT/US 87/01459 (SA 17948)

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 18/11/87

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0148605	17/07/85	WO-A- 8502610	20/06/85
		AU-A- 3746785	26/06/85
		JP-T- 61501627	07/08/86
		US-A- 4703008	27/10/87
WO-A- 8503079	18/07/85	AU-A- 3994585	30/07/85
		EP-A- 0169239	29/01/86
		JP-T- 61501152	12/06/86
WO-A- 8603520	19/06/86	AU-A- 5313486	01/07/86
		EP-A- 0205564	30/12/86
		JP-T- 62501010	23/04/87
WO-A- 8604920	28/08/86	AU-A- 5513586	10/09/86
		EP-A- 0217822	15/04/87
		JP-T- 62501957	06/08/87
EP-A- 0236059	09/09/87	JP-A- 62198388	02/09/87